CorMedix Inc. Announces FDA Approval of DefenCath ® to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients

First and only FDA-approved antimicrobial catheter lock solution in the U.S. – Company expects DefenCath to be available in Q1 2024 in the inpatient setting BERKELEY HEIGHTS, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. CRMD, a biopharmaceutical company focused on developing and…#fda #defencath #berkeleyheights #cormedixinc #crbsis #josephtodisco #cormedix #phase3lock #edwardvhickey #uscongress
Source: Reuters: Health - Category: Consumer Health News Source Type: news